Ann: MSB Clinical Program Update For MPC-150-IM In Heart Failure, page-21

So Mesoblast give us a comprehensive update on the CHF program, which includes another passed interim analysis.

It also reinforces the fact they are actively seeking accelerated approval through their RMAT designation.

If successful, MSC 150-IM could be in market in 2019.

That is something worth reminding people of.

I see nothing wrong in MSB providing context when making such announcements, it may look like they are repeating old information- but somebody may be reading this for the first time.

So an announcement that caters for the new and old investor is fine by me